A new vaccination strategy designed to induce antibodies that recognize the apex of the HIV Env protein uses Env trimers displayed on liposomes to increase their density and orient them correctly. This presentation enhanced apex-focused antibody responses in macaques, and the monoclonal antibodies isolated after immunization showed binding modes and structural features resembling human broadly neutralizing antibodies (bNAbs), indicating that the vaccine can steer the antibody response toward this vulnerable site.
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducer potentially useful for the treatment of cancer.
Ono Pharmaceutical Co. Ltd. has synthesized bridged bicyclic compounds acting as endosomal/lysosomal proton channel TMEM175 activators. As such, they are described as potentially useful for the treatment of inflammatory disorders, lysosomal storage diseases, autoimmune disease and Parkinson’s disease.
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the treatment of neurological and psychiatric disorders.
Work at Pheon Therapeutics Ltd. has led to the development of new antibody-drug conjugates comprising an antibody or antigen binding fragment targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drug. They are intended for use in the treatment of cancer.
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Ly6E is a cell‑surface protein involved in tumor growth and immune evasion that is overexpressed across multiple solid tumor types, with limited expression in normal tissues. At AACR, researchers from Merck KGaA presented the preclinical characterization of M-7437, an anti-Ly6E ADC with a topoisomerase 1 (TOP1) inhibitor payload.
Shanghai Ailux Biotechnology Co. Ltd. and Ailux Inc. have presented preclinical data regarding the characterization of ALX-006, a 2+2 symmetric IgG1 PD‑1×VEGF bispecific antibody developed and designed for dual PD‑L1 and VEGF blockade as a cancer immunotherapeutic.
PD-1 and LAG-3 are both inhibitory immune checkpoints known for limiting T cell activity in cancer. Blocking PD-1 and LAG-3 reprograms suppressive macrophages and sustains antitumor efficacy independently of T cells. Chinese researchers reported the development of BsPep-IMDQ, a bispecific peptide-drug conjugate (PDC) designed to target LAG-3 and PD-1 simultaneously.
RSS
